Alphatec Holdings, Inc Q3 2026 Earnings Call - ALPHATEC HOLDINGS INC

Explicit Guidance:

• Full-Year 2026 Total Revenue: Reduced to approximately $862 million (up ~13% YoY), previously higher; reflects $102 million of surgical dollar growth.
• Full-Year 2026 Surgical Revenue: Expected at $789 million (up ~15% YoY); implies ~17% growth in surgical hardware and flat biologics revenue YoY.
• Full-Year 2026 EOS Revenue: Expected at $73 million (flat YoY).
• Full-Year 2026 Adjusted EBITDA: Expected at $137 million (approx. 16% margin), representing ~47% YoY growth.
• Full-Year 2026 Free Cash Flow: Expected at $10 million, implying ~$15 million in Q4 2026.
• 2026 Performance Implied Metrics: High teen surgical case volume growth (+20% in Q3); ~3% decline in revenue per case driven by lower biologics attachment.
• 2027 Long-Range Plan (LRP) Targets: Reference to $1 billion revenue and $180 million adjusted EBITDA targets, though specific 2027 guidance is not yet provided; management views the second half of 2026 as a representative jumping-off point for 2027.
• International Supply Constraint Impact: Expected to reduce international sales by $3 million for the full year 2026, with resolution anticipated as of 2027.

Business-Segment Outlook:

• Surgical Hardware: Expected to drive all surgical growth in 2026 with ~17% growth; consistent long-term trend expected to continue.
• Biologics: Expected to be flat year-over-year for 2026 (contributing $0 growth vs. historical $15–$25 million); Q4 expected to remain flat sequentially vs. Q3; management expects improvement over time but cites unpredictability in timing/effectiveness of corrective sales discipline measures.
• Procedure Volumes: Thoracolumbar volumes showing slower growth reflecting broader market softness; Cervical volumes growing strongly, offsetting thoracolummar weakness; overall procedure volume expected to remain in the high teens to 20% growth range.
• EOS Capital: Revenue flat in 2026 due to "lumpy" capital availability and installation timing; demand remains healthy, but quarter-over-quarter growth is expected to be inconsistent in 2026 before improving in 2027.
• Valence (Surgical Robotics): Expanding indications from Lateral to Posterior (Navigated T-Lift); early feedback confirms workflow integration; expected to be a "tailwind" for 2027 as utility broadens across procedures.
• Surgeon Adoption: New surgeon growth rate of ~25% maintained; younger surgeon cohort increasing, initially impacting revenue per case due to less complex cases, but serving as a foundational long-term growth driver.
• Pediatric & Deformity: Viewed as a longer-term opportunity; expected to drive more adult deformity volume in the near term as pediatric adoption scales; EOS Edge now in >70% of academic institutions with fellowship programs to influence future surgeons.

Market and Competitive Outlook:

• Market Volume: Orthopedic spine market growth estimated at low-single-digit rates in 2026, down from mid-single-digit expectations earlier in the year; softness concentrated in thoracolumbar procedures.
• Pricing Dynamics: Pricing environment described as "stable" with no anticipated changes for Q4 2026 or early 2027; no significant price pressure expected.
• Competition: Biologic leakage driven by hospital RFPs favoring lower-priced competitors; management views competitors copying their procedures as "promoting the technique" but notes ATEC retains the "last best effort" advantage due to deep clinical integration.
• Share Shifts: Continued share acquisition expected via strong procedure volume growth (20%) and surgeon adoption (25%), outpacing market despite per-case revenue compression.
• Home Procedures: Growth in home procedures viewed positively as it validates and expands the total addressable market for ATEC's core PTP (Prone Transpsoas) technique.

Macro / Industry Outlook:

• Hospital Economics: Hospitals actively cutting costs via RFPs, specifically targeting biologics to save money, leading to leakage in ATEC's procedural value.
• Regulatory/Timing: "Longest day" (17 years) for clinical discovery to routine practice cited; management aims to shorten this via EOS Insight and partnership with academic leaders (Columbia, UCSF, BNI) to integrate new deformity classifications into the platform.
• FX/International: International business expected to recover from supply constraints in 2027; Australia, New Zealand, and Japan identified as key growth markets with ongoing sterilization/packaging compliance efforts.
• Rates/Economy: Implicitly referenced via "capital availability" challenges affecting EOS installation timing and hospital budget cycles.

Strategic Initiatives:

• Sales Discipline: Implementing "carrot and stick" approach to sales force to correct biologics attachment leakage; holding sales management accountable for exclusivity and contract compliance.
• Leadership: Hired Tommy Carls as EVP, Data Intelligence and Strategy (Sept) to lead EOS Edge, EOS Insight, data, and analytics strategy.
• EOS Insight Council: Inaugural council of 70+ KOLs convened to accelerate platform evolution into a continuously learning intelligence platform; focus on predictive surgical planning and patient-specific rods.
• OsteoAdapt: Developing next-generation biologic to replace BMP (currently dominated by Medtronic); expects to enter market "sprinting" rather than "jogging" once foundation is built; timeline not specific but implied future growth driver.
• Valence Expansion: Extending platform utility beyond lateral to posterior procedures (T-LIFT) to become the "operating system" for spine surgery.
• EOS Edge: Continued focus on placing systems in academic institutions to capture the next generation of surgeons; 70% penetration in fellowship programs.

Risks and Headwinds to Outlook:

• Biologics Leakage: Continued risk of lower ACV if sales discipline does not improve; hospitals seeking lower-cost biologics from competitors during RFPs.
• Market Softness: Thoracolumbar procedure volume softness may persist into Q4 2026 and potentially 2027; management is monitoring closely.
• Capital Timing: EOS capital orders face lumpy installation dynamics and extended periods between order placement and hospital commitment due to budget cycles.
• Supply Chain: International supply constraints (packaging/sterilization defects) impacted Q4 2026 guidance but are expected to be resolved by 2027.
• Execution Risk: Management explicitly states "timing and effectiveness" of biologics corrective measures are "difficult to predict," warranting a cautious stance for 2027.
• New Surgeon Mix: Younger surgeons initially performing less complex cases may compress revenue per case in the near term before scaling.

Management Tone on the Future:

• Confidence Level: High confidence in the long-term "procedural thesis" and platform fundamentals; described as "undoubtedly earning the procedures."
• Frustration vs. Resolve: Significant frustration expressed regarding biologics leakage ("irritating," "maddening," "like getting pickpocketed"), coupled with a commitment to "own it" and aggressively address it.
• Optimism: CEO Pat Miles stated, "Our best days are yet ahead" and "We are profoundly inspired by what we are building together"; emphasized resilience and leverage despite revenue miss.
• Hedging: Caution advised regarding 2027 guidance until biologics recovery is clearer; management is "not giving specific guidance for 2027" but viewing H2 2026 as the best indicator.
• Long-Term View: Reiterated "long player" status; confident in the ability to translate growth into margin and cash flow despite short-term headwinds.

Miscellaneous:

• Capital Structure: Fully repaid remaining balance of 2026 convertible notes using cash on hand; simplified structure with $135 million total liquidity ($80M cash + $55M borrowing capacity).
• Cost Discipline: Adjusted EBITDA margins expected to expand further in Q4 to ~18%, driven by gross margin improvements and operating leverage.
• Data Strategy: Focus on converting EOS imaging data into a proprietary dataset for predictive planning and institutional value; "OS" analogy for Valence to encompass the entire procedural workflow.